DUX4 and facioscapulohumeral muscular dystrophy: Together, these findings demonstrate that batimastat, a pan-MMP inhibitor, effectively improves muscle histopathology in DUX4-induced FSHD by attenuating both fibrotic and inflammatory responses through MMP inhibition.